Our study demonstrates that A20 mRNA therapy effectively suppresses fibrosis by restoring A20 expression, inhibiting TRAF6/NF-κB signaling, and downregulating DREAM in an in vivo model of SSc. The gene discussed is NFKB1; the disease is systemic sclerosis.